Efficacy of Phentolamine in Prevention of Contrast-Associated Acute Kidney Injury After Complex PCI

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2025

Conditions
CA-AKI - Contrast-Associated Acute Kidney InjuryCoronary Artery DiseaseAcute Coronary SyndromeAdrenergic Receptor Antagonist Adverse Reaction
Interventions
DRUG

Phentolamine

In addition to the conventional management, patients will receive phentolamine (Rogitamine; Egypharma) infusion at a rate of 0.5 μgm/kg/min for the first 15 minutes after a bolus dose of 5 mg. If significant hemodynamic change occurred, the infusion then will be discontinued and the patient will be excluded. Otherwise, the dose will be uptitrated gradually 0.5-2 ugm/kg/min and the infusion will be continue for 12 hours.

Trial Locations (1)

Unknown

RECRUITING

Badr university hospital, Badr

All Listed Sponsors
lead

Helwan University

OTHER